Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)
NCT ID: NCT04025424
Last Updated: 2021-12-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
350 participants
OBSERVATIONAL
2019-06-15
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The duration of the follow-up will be 12-60 months. Data from medical records will be retrospectively collected at different points in time. The first data extraction will consist of collecting data from the initial level (before treatment with immune checkpoints inhibitors (anti-PD1 / PDl1) before the end of the recruitment period for this study (up to 3 years of follow-up). Two additional annual data collections are planned for display additional follow-up and data for patients who will survive.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Skin melanoma, retrospective
* 1\) Clinically and morphologically verified diagnosis of skin melanoma or melanoma metastases without an identified primary lesion;
* 2\) The availability of basic clinical information about the patient and the course of his illness;
Genetic tests of the available tumor and plasma samples
Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
Hodgkin disease, retrospective
* 1\) Clinically and morphologically verified diagnosis of Hodgkin disease (any histological variant);
* 2\) The availability of basic clinical information about the patient and the course of his illness;
Genetic tests of the available tumor and plasma samples
Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
Uveal melanoma, retrospective
* 1\) Clinically and morphologically verified diagnosis of uveal melanoma (any histological variant);
* 2\) The availability of basic clinical information about the patient and the course of his il
Genetic tests of the available tumor and plasma samples
Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
Skin melanoma, proscpective
* 1\) Clinically and morphologically verified diagnosis of metastatic melanoma;
* 2\) The availability of basic clinical information about the patient and the course of his illness;
Genetic tests of the available tumor and plasma samples
Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
Lung cancer, procpective
* 1\) Clinically and morphologically verified diagnosis of metastatic or inoperable squamous cell lung cancer;
* 2\) The availability of basic clinical information about the patient and the course of his illness;
* 3\) The presence of indications for therapy with a PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy;
Genetic tests of the available tumor and plasma samples
Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genetic tests of the available tumor and plasma samples
Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 2 injections (or 10 weeks) of ICI (PD1, PDl1 blockers, including but not limited to such drugs as nivolumab, pembrolizumab, prolglimab, atezolizumab, avelumab, durvalumab, spratalizumab)
* Deceased patients meet the criteria; signing the informed consent of the legal representative of the deceased patient is not required
* Cohort 1 (retrospective cohort of skin melanoma patients)
* 1\) Clinically and morphologically verified diagnosis of skin melanoma or melanoma metastases without an identified primary focus;
* 2\) The availability of basic clinical information about the patient and the course of his illness;
* 3\) Therapy with a PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy (at least 2 injections);
* 4\) Evaluation of the effect of immunotherapy
* 5\) Availability of tumor material (paraffin blocks) for morphological, immunohistochemical and molecular genetic studies, obtained no earlier than 24 months. before initiating therapy with a PD-1 or PD-L1 inhibitor;
* 8\) Patient-signed informed consent in case the patient is alive
* Cohort 2 (Hodjkin disease - retrospective)
* 1\) Clinically and morphologically verified diagnosis of Hodgkin disease (any histological variant);
* 2\) The availability of basic clinical information about the patient and the course of his illness;
* 3\) Availability of tumor material (paraffin blocks) for morphological, immunohistochemical and molecular genetic studies;
* 4\) Patient signed informed consent.
* Cohort 3 (Uveal melanoma - retro)
* 1\) Clinically and morphologically verified diagnosis of uveal melanoma (any histological variant);
* 2\) The availability of basic clinical information about the patient and the course of his illness;
* 3\) Availability of tumor material (paraffin blocks) for morphological, immunohistochemical and molecular genetic studies;
* 4\) Patient signed informed consent.
* Cohort 4 (melanoma of the skin - prospective)
* 1\) Clinically and morphologically verified diagnosis of metastatic melanoma;
* 2\) The availability of basic clinical information about the patient and the course of his illness;
* 3\) Indications for therapy with a PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy;
* 4\) The possibility of including the patient in the present study before the first course of immunotherapy;
* 5\) Availability of tumor material (paraffin blocks and histological glass preparations) for morphological, immunohistochemical and molecular genetic studies obtained no earlier than 2 years before the planned start of immunotherapy with a standard PD-1 inhibitor;
* 6\) Separate patient consent to a repeated biopsy of the tumor focus before the planned start of immunotherapy with a PD-1 or PD-L1 inhibitor, if the existing tumor material was obtained earlier than 2 years before the planned start of immunotherapy
* 7\) Availability of samples of biological fluids collected before the start of immunotherapy and after the first course of immunotherapy for molecular genetic studies of circulating tumor DNA;
* 8\) Evaluation of the effect of therapy in the framework of local practice in accordance with the criteria of RECIST 1.1
* 9\) Signed by the patient informed consent to participate in the study.
* Cohort 5 (squamous cell lung cancer - prospective)
* 1\) Clinically and morphologically verified diagnosis of metastatic or inoperable squamous cell lung cancer;
* 2\) The availability of basic clinical information about the patient and the course of his illness;
* 3\) The presence of indications for therapy with a PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy;
* 4\) The possibility of including the patient in the present study before the first course of immunotherapy;
* 5\) Availability of tumor material (paraffin blocks) for morphological, immunohistochemical and molecular genetic research, obtained no earlier than 2 years before the planned start of immunotherapy with a standard PD-1 inhibitor;
* 6\) Separate patient consent to a repeated biopsy of the tumor focus before the planned start of immunotherapy with a PD-1 or PD-L1 inhibitor, if the existing tumor material was obtained earlier than 2 years before the planned start of immunotherapy
* 7\) Availability of samples of biological fluids collected before the start of immunotherapy and after the first course of immunotherapy for molecular genetic studies of circulating tumor DNA;
* 8\) Evaluation of the effect of therapy in the framework of local practice in accordance with the criteria of RECIST 1.1
* 9\) Signed by the patient informed consent to participate in the study.
Exclusion Criteria
\- 1) It is not allowed to conduct other immunotherapy (anti-CTLA4, vaccines, etc.) to patients before the course of therapy with a PD-1 or PD-L1 inhibitor in a standard dosage in monotherapy
* Cohort 2 (Hodgkin disease - retrospective)
* Cohort 3 (Uveal melanoma - retro)
* Cohort 4 (melanoma of the skin - prospective)
* 1\) It is not allowed to include patients who have previously undergone other immunotherapy (anti-CTLA4, vaccines, etc.) before the course of therapy with the PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy
* 2\) It is not allowed to include patients who are scheduled for combination immunotherapy (anti-PD1 + anti-CTLA4, vaccines, etc.) after inclusion in this study
* Cohort 5 (squamous cell lung cancer - prospective)
* 1\) It is not allowed to include patients who have previously undergone other immunotherapy (anti-CTLA4, vaccines, etc.) before the course of therapy with the PD-1 or PD-L1 inhibitor in the standard dosage in monotherapy
* 2\) It is not allowed to include patients who are scheduled for combination immunotherapy (anti-PD1 + anti-CTLA4, vaccines, etc.) after inclusion in this study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Russian Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Igor Samoylenko
MD, PhD, Principal Investigator, Senior Researcher, Tumor biotherpay Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
N.N. Blokhin Russian Cancer Research Center
Moscow, Moscow, Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Igor Samoylenko, MD, PhD
Role: primary
Kirill Baryshnikov, MD, PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICIPRESIST-052019
Identifier Type: -
Identifier Source: org_study_id